Irsenontrine maleate  (Synonyms: E2027 maleate)

Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases^[1][2].

PDE9^[1]

Irsenontrine (0.3, 3.3 mg/kg; p.o.) maleate exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats^[1].
Irsenontrine (1 mg/kg; p.o.) maleate and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

506.51

C₂₆H₂₆N₄O₇

1630083-70-3

O=C1NC2=C(C=CC(C3=C(C)C(OC)=NC=C3C)=C2)C4=C1C=NN4[C@@H]5COCC5.O=C(O)/C=C\C(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1

  [2]. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319.  [Content Brief]

  [3]. Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases